Analysts are positive on Raffles Medical Group in light of strong 9MFY2022 ended September results with a net profit growth of $98.2 million, up 57.3% y-o-y.DBS Group Research analyst Rachel Tan has kept a “buy” rating on Raffles Medical with an unchanged target price of $1.64.For 3QFY2022, the ...

Raffles Medical Group (RMG) has reported profit after tax of $38.3 million for the 3QFY2022 ended Sept 30, 23.6% higher y-o-y.Revenue for the 3QFY2022 increased by 6.5% y-o-y to $199.5 million due to the return of the foreign patients seeking treatment, as well as the return of domestic patients ret...

THE following companies saw new developments that may affect trading of their securities on Monday (Oct 31):

PRIVATE healthcare provider Raffles Medical reported a 62.1 per cent year-on-year increase in net profit to S$38.3 million in Q3, from the S$23.6 million posted in the same period last year. 

Stay defensive and look for value opportunities among Singapore Exchange (SGX) names, says RHB Group Research analyst Shekhar Jaiswal in a Singapore strategy note.“Given the rising global macroeconomic risks, equity markets are likely to continue being volatile. Investors should maintain a defensi...

Private hospital groups such as Raffles Medical Group and IHH Healthcare may stand to benefit from the rise in Covid-19 cases, says DBS Group Research analyst Rachel Tan.Referring to a report by broadsheet The Straits Times on Oct 20, Tan noted that public hospitals in Singapore are experiencing a b...

CGS-CIMB has raised its target price for Raffle Medical Group as it expects the company to play a significant role in supporting the government’s public health efforts, in light of the recent surge in Covid-19 cases.

RAFFLES Medical and other private hospitals, such as IHH Healthcare, are expected to benefit from the current bed crunch at public hospitals, according to a report by DBS on Friday (Oct 21). 

RHB Group Research analyst Shekhar Jaiswal has kept “buy” on Raffles Medical while lowering his target price to $1.60 from $1.65 previously.In his report dated Oct 13, Jaiswal also reduced his earnings estimates for the group by 3% each for the FY2023 and FY2024.The lowered target price and earn...

DBS Group Research analysts Yeo Kee Yan and Janice Chua expect the upcoming 3QFY2022 season commencing mid-October to witness a mix of ups and downs, where market volatility will likely bring several potential surprises for various companies.According to the analysts, certain upside surprises could ...

DBS Group Research analysts Yeo Kee Yan and Janice Chua are anticipating more “sideways gyrations” for the benchmark Straits Times Index (STI) as the Fed continues to be bent on arresting inflation by raising rates, even if it comes at the expense of sub-par growth.To the analysts, the better-th...

DBS Group Research analysts Yeo Kee Yan and Janice Chua believe that the 2QFY2022 performance of SGX-listed counters has “allayed” concerns of further lows.In a report dated Aug 24, the analysts write that the 2QFY2022 results season “debunked immediate slowdown concerns”, reflecting Singapo...

Policymakers and central bankers are now compelled to deal with higher-than-expected inflationary pressures, which — if left uncurbed — risk destabilising financial and economic systems and not merely weakening the spending power of consumers.While the fight to rein in inflation is not new, the ...

Healthcare is a “beneficiary” during periods of high inflation, says DBS Research analyst Rachel Tan in her healthcare industry report dated Aug 16.Given the global supply disruptions and ongoing geopolitical tensions, Singapore’s consumer price index (CPI) spiked from 2.29% in 2021 to 6.7% in...

While Singapore’s economy in the first half had enjoyed a “powerful” post-pandemic boost, this tailwind is expected to dissipate in the second half of the year. “We think global headwinds will start to dominate,” warns Maybank’s co-head for macro research Chua Hak Bin.Maybank sees Singap...